
    
      This is an Individual Patient Expanded Access IND with the primary goal of treatment for an
      individual with Primary Lateral Sclerosis. There are no FDA approved, fully restorative
      treatments for Primary Lateral Sclerosis. The subject will receive a total of twelve
      autologous monthly HB-adMSCs infusions of 200 million cells.
    
  